In Vitro Antibacterial Activity of Amikacin and Ticarcillin, Alone and in Combination, Against
            <i>Pseudomonas aeruginosa</i>

Yoshikawa, Thomas T.; Shibata, Sharon A.

doi:10.1128/aac.13.6.997

Cited by 16 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although antimicrobial synergy appears to be best established for ␤-lactam-aminoglycoside combinations, similar data on synergistic activity have emerged for combinations of ␤-lactams and fluoroquinolones (14,50,77,96,99,132,168,183,189,205,252,253). In vitro synergy between ␤-lactams and fluoroquinolones against Gram-negative organisms has ranged from 17% to 82% (96,119,168).…”

Section: Synergymentioning

confidence: 99%

Combination Therapy for Treatment of Infections with Gram-Negative Bacteria

2012

View full text Add to dashboard Cite

SUMMARY Combination antibiotic therapy for invasive infections with Gram-negative bacteria is employed in many health care facilities, especially for certain subgroups of patients, including those with neutropenia, those with infections caused by Pseudomonas aeruginosa , those with ventilator-associated pneumonia, and the severely ill. An argument can be made for empiric combination therapy, as we are witnessing a rise in infections caused by multidrug-resistant Gram-negative organisms. The wisdom of continued combination therapy after an organism is isolated and antimicrobial susceptibility data are known, however, is more controversial. The available evidence suggests that the greatest benefit of combination antibiotic therapy stems from the increased likelihood of choosing an effective agent during empiric therapy, rather than exploitation of in vitro synergy or the prevention of resistance during definitive treatment. In this review, we summarize the available data comparing monotherapy versus combination antimicrobial therapy for the treatment of infections with Gram-negative bacteria.

show abstract

Section: Synergymentioning

confidence: 99%

Combination Therapy for Treatment of Infections with Gram-Negative Bacteria

2012

View full text Add to dashboard Cite

show abstract

“…While more than one antimicrobial is frequently needed to cover the entire spectrum of suspected microorganisms in severe sepsis and septic shock, combination antimicrobial therapy is the use of more than one antimicrobial to target the same microorganism through different pharmacologic mechanisms of action to achieve an additive or synergistic killing effect leading to more rapid clearance of the infection [69–71]. Historically, evidence supporting antimicrobial synergism to this effect can be found with β-lactam/aminoglycoside combinations [72–75]. Similar findings have also been demonstrated for β-lactam/fluoroquinolone combinations [76–79].…”

Section: Optimization Of Antimicrobial Potencymentioning

confidence: 99%

Empiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance

Liang

Kumar

2015

Curr Infect Dis Rep

View full text Add to dashboard Cite

Mortality and morbidity in severe sepsis and septic shock remain high despite significant advances in critical care. Efforts to improve outcome in septic conditions have focused on targeted, quantitative resuscitation strategies utilizing intravenous fluids, vasopressors, inotropes, and blood transfusions to correct disease-associated circulatory dysfunction driven by immune-mediated systemic inflammation. This review explores an alternate paradigm of septic shock in which microbial burden is identified as the key driver of mortality and progression to irreversible shock. We propose that clinical outcomes in severe sepsis and septic shock hinge upon the optimized selection, dosing, and delivery of highly potent antimicrobial therapy.

show abstract

“…Bactericidal synergy was felt to be present if the MBCs determined for both single antibiotics each fell fourfold or greater when these agents were used in combination [20]. To verify the occurrence of bac tericidal synergy, timed-kill assays were also per formed.…”

Section: Methodsmentioning

confidence: 99%

“…Minimum inhibi tory concentrations (MICs), minimum bactericidal concentrations (MBCs) and the bactericidal synergy of amikacin and ticarcillin for this PA strain were de termined by the checkerboard microtiter technique [20]. Overnight MH broth cultures of PA-96 were ad justed to a McFarland No.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Therapy of Experimental Pseudomonas Endocarditis with High-Dose Amikacin and Ticarcillin

Choi¹,

Bayer²,

Fujita³

et al. 1983

Chemotherapy

Self Cite

View full text Add to dashboard Cite

Right-sided infective endocarditis due to Pseudomonas aeruginosa was induced in 130 rabbits. Animals received either: (1) no therapy (controls); (2) standard-dose amikacin (AMK) (15 mg/kg/day) plus ticarcillin (300 mg/kg/day), or (3) high-dose AMK (20 or 25 mg/kg/day) plus ticarcillin, for 20 days. Animals in each treatment group were evaluated at 10 days after therapy for bacteriologic relapse. Both standard-and high-dose AMK regimens significantly decreased mortality and Pseudomonas aeruginosa vegetation titers versus controls (p < 0.01, p < 0.05, respectively). Despite significantly higher serum AMK levels at 25 mg/kg/day, there was no significant difference in mean vegetation titers, percent of vegetations sterilized, or posttherapy bacteriologic relapse in the three treatment groups. AMK at 20 or 25 mg/kg/day (but not at 15 mg/kg/ day) significantly reduced the incidence of pulmonary infarction versus untreated controls (p < 0.01).

show abstract

In Vitro Antibacterial Activity of Amikacin and Ticarcillin, Alone and in Combination, Against Pseudomonas aeruginosa

Cited by 16 publications

References 12 publications

Combination Therapy for Treatment of Infections with Gram-Negative Bacteria

Combination Therapy for Treatment of Infections with Gram-Negative Bacteria

Empiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance

Therapy of Experimental Pseudomonas Endocarditis with High-Dose Amikacin and Ticarcillin

Contact Info

Product

Resources

About